Lilly's Zepbound Receives FDA Approval for Sleep Apnea

Eli Lilly and Company (LLY) announced that the FDA has approved its popular obesity drug, Zepbound (tirzepatide) for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. OSA is a common sleep-related breathing disorder that causes repeated interruptions in breathing (apnea) or shallow breathing (hypopnea) during sleep. OSA marks the second indication for Zepbound. The drug was approved to treat obesity or overweight issues in November 2023.With the approval, Zepbound becomes the ...